PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29459785-6	2018	Structural and functional analyses reveal the difference between GPT and MraY in their mechanisms of inhibition by tunicamycin.	Tunicamycin	115-126	glutamic--pyruvic transaminase	Homo sapiens	65-68	
29459785-2	2018	The enzyme UDP-N-acetylglucosamine:dolichyl-phosphate N-acetylglucosaminephosphotransferase (GlcNAc-1-P-transferase or GPT) catalyzes the first and committed step of N-linked glycosylation in the endoplasmic reticulum membrane, and it is the target of the natural product tunicamycin.	Tunicamycin	272-283	glutamic--pyruvic transaminase	Homo sapiens	119-122	
29459785-3	2018	Tunicamycin has potent antibacterial activity, inhibiting the bacterial cell wall synthesis enzyme MraY, but its usefulness as an antibiotic is limited by off-target inhibition of human GPT.	Tunicamycin	0-11	glutamic--pyruvic transaminase	Homo sapiens	186-189	
29459785-5	2018	Here we present crystal structures of human GPT in complex with tunicamycin.	Tunicamycin	64-75	glutamic--pyruvic transaminase	Homo sapiens	44-47	
31566068-1	2020	Tunicamycins, which are nucleoside natural products, inhibit both bacterial phospho-N-acetylmuraminic acid (MurNAc)-pentapeptide translocase (MraY) and human UDP-N-acetylglucosamine (GlcNAc): polyprenol phosphate translocase (GPT).	Tunicamycin	0-12	glutamic--pyruvic transaminase	Homo sapiens	226-229	
30637701-12	2018	Inhibition of GPT with tunicamycin downregulates the DPMS catalytic activity quantitatively.	Tunicamycin	23-34	glutamic--pyruvic transaminase	Homo sapiens	14-17	
9878696-6	1999	The antibiotic tunicamycin completely inhibited GPT activity at a concentration of 100-200 ng ml(-1) and an IC50 of 40 ng ml(-1), but had little effect on the other two enzymes.	Tunicamycin	15-26	glutamic--pyruvic transaminase	Homo sapiens	48-51	
22936838-2	2012	Its impairment by tunicamycin [a competitive inhibitor of N-acetylglucosaminyl 1-phosphate transferase (GPT)] has been known to inhibit neo-vascularization (i.e., angiogenesis) in humanized breast tumor due to an induction of ER stress-mediated unfolded protein response (UPR).	Tunicamycin	18-29	glutamic--pyruvic transaminase	Homo sapiens	104-107	
35454076-9	2022	We tested a small biological molecule, Tunicamycin, that blocks a specific step of the protein N-glycosylation pathway in the endoplasmic reticulum (ER), i.e., the catalytic activity of N-acetylglusosaminyl 1-phosphate transferase (GPT).	Tunicamycin	39-50	glutamic--pyruvic transaminase	Homo sapiens	232-235	
35370192-5	2022	The usefulness of tunicamycin as antibacterial agents is limited by off-target inhibition of human UDP-N-acetylglucosamine (GlcNAc): polyprenol phosphate translocase (GPT).	Tunicamycin	18-29	glutamic--pyruvic transaminase	Homo sapiens	167-170	
35370192-7	2022	Next, the minimum structural requirements for tunicamycin V for MraY inhibition were established by systematic structure-activity relationship studies with truncated analogs of tunicamycin V. Our collaborative study elucidated a crystal structure of human GPT in complex with tunicamycin.	Tunicamycin	46-57	glutamic--pyruvic transaminase	Homo sapiens	256-259	
35370192-7	2022	Next, the minimum structural requirements for tunicamycin V for MraY inhibition were established by systematic structure-activity relationship studies with truncated analogs of tunicamycin V. Our collaborative study elucidated a crystal structure of human GPT in complex with tunicamycin.	Tunicamycin	177-188	glutamic--pyruvic transaminase	Homo sapiens	256-259	
35370192-7	2022	Next, the minimum structural requirements for tunicamycin V for MraY inhibition were established by systematic structure-activity relationship studies with truncated analogs of tunicamycin V. Our collaborative study elucidated a crystal structure of human GPT in complex with tunicamycin.	Tunicamycin	276-287	glutamic--pyruvic transaminase	Homo sapiens	256-259